经肝动脉化疗栓塞术联合全身化疗治疗乳腺癌肝转移的效果及安全性  

Efficacy and safety of transcatheter arterial chemoembolization combined with systemic chemotherapy in the treatment of breast cancer with liver metastasis

作　　者：李成学[1] 杨凯[1] 张红[1] 

机构地区：[1]安阳钢铁集团有限责任公司职工总医院介入科,455004

出　　处：《国际医药卫生导报》2016年第23期3609-3611,共3页International Medicine and Health Guidance News

摘　　要：目的探究经肝动脉化疗栓塞术联合全身化疗治疗乳腺癌肝转移的效果及安全性。方法对照组给予乳腺癌全身化疗治疗，观察组在全身化疗2个周期后，联合经肝动脉化疗栓塞术（TACE）治疗，观察对比两组近期临床疗效和安全性。结果观察组近期有效率为62．2％，明显高于对照组的35．6％（P〈0．05）；两组Ⅲ～Ⅳ级毒副反应发生情况均无统计学差异（P〉0．05）；观察组中位生存期为（26．1±5．3）个月，明显多于对照组的（14．2±4．2）个月，组间比较差异有统计学意义（P〈0．05）。结论该组合疗法治疗乳腺癌肝转移的近期临床疗效确切，有助于延长患者的生存期，且用药安全性较高。Objective To explore the efficacy and safety of transcatheter arterial chemoembolization combined with systemic chemotherapy in the treatment of breast cancer with liver metastasis. Methods Control group was given breast cancer systemic chemotherapy, and observation group was given transcatheter arterial chemoembolization （TACE） after 2 cycles of systemic chemotherapy. Compared the clinical efficacy in the near future and safety of two groups. Results The recent effective rate of observation group was 62.2%, significantly higher than 35.6% of control group （P〈0.05）. There was no statistically significant difference in the incidence of Ⅲ-Ⅳdegree toxic and side effect between two groups （P〉0.05）. The median survival of observation group was （26.1±5.3） months, significantly longer than （14.2±4.2） months of control group, with statistically significant difference between two groups （P〈0.05）. Conclusion The combination therapy is effective in the treatment of breast cancer with liver metastasis in the near future, which can prolong the survival time of patients, with high safety of drug use.

关 键 词：肝动脉化疗栓塞术 全身化疗 乳腺癌 肝转移 

分 类 号：R735.7[医药卫生—肿瘤]